Osvaldo Daniel Messina

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Kenneth G. Saag, Rachel B. Wagman, Piet Geusens et al. · The Lancet Diabetes & Endocrinology · 2018 · 191 citations

Bone Disease, Bone Health, Glucocorticoid-induced Osteoporosis +6

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

A H Sarris, K. O. Kliche, P. Pethambaram et al. · Annals of Oncology · 1999 · 162 citations · Full text

Inflammation, Clinical Immunology, Cytokine +10

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

Kenneth G. Saag, Nicola Pannacciulli, Piet Geusens et al. · Arthritis & Rheumatology · 2019 · 135 citations · Full text

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

René Westhovens, William F. C. Rigby, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2021 · 134 citations · Full text

Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease

Aaron Broadwell, Arkadi Chines, Peter R. Ebeling et al. · The Journal of Clinical Endocrinology & Metabolism · 2020 · 87 citations · Full text